Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 15/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 14/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 14/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834364 | 0.94 | FGFR1 (0.44) | FGFR1FGFR2FGFR3ACVR1RAF1 | |
| SCHEMBL2327299 | 0.94 | FGFR1 (0.44) | FGFR1FGFR2FGFR3ACVR1RAF1 | |
| SCHEMBL2327026 | 0.92 | FGFR1 (0.44) | FGFR1FGFR2FGFR3ACVR1RAF1 | |
| SCHEMBL12440209 | 0.90 | MET (0.43) | ACVR1MET | |
| SCHEMBL13968444 | 0.85 | FEN1 (0.43) | — | |
| SCHEMBL2327444 | 0.84 | MET (0.41) | RAF1MAP2K1MET | |
| SCHEMBL12440059 | 0.84 | MET (0.45) | RAF1MAP2K1MET | |
| SCHEMBL2327165 | 0.84 | MET (0.42) | ACVR1MET | |
| SCHEMBL12439733 | 0.83 | MET (0.46) | FGFR1FGFR2FGFR3MET | |
| SCHEMBL12441209 | 0.83 | MET (0.47) | FGFR1FGFR2FGFR3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2011095196-A1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | FGFR1 2980/4885FGFR2 3308/4885FGFR3 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.